Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 7/20 | 0.45 |
| ▸ | IKBKB | O14920 | 1/20 | 0.42 |
| ▸ | KAT2B | Q92831 | 2/20 | 0.39 |
| ▸ | IDH2 | P48735 | 1/20 | 0.38 |
| ▸ | CDK1 | P06493 | 3/20 | 0.37 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.37 |
| ▸ | CDK2 | P24941 | 3/20 | 0.37 |
| ▸ | CCNA1 | P78396 | 3/20 | 0.37 |
| ▸ | CDK4 | P11802 | 3/20 | 0.37 |
| ▸ | CCND1 | P24385 | 3/20 | 0.37 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.37 |
| ▸ | MAPK7 | Q13164 | 1/20 | 0.37 |
| ▸ | RET | P07949 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.37 |
| ▸ | CCND3 | P30281 | 1/20 | 0.37 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10156667 | 0.84 | HRH4 (0.42) | HRH4 | |
| SCHEMBL4125312 | 0.71 | IKBKB (0.51) | HRH4IKBKBKAT2BCDK1CCNA2 | |
| SCHEMBL14147226 | 0.71 | MAPK1 (0.54) | HRH4IKBKBKAT2BCDK1CCNA2 | |
| SCHEMBL28447539 | 0.70 | KAT2B (0.45) | HRH4IKBKBKAT2BCDK1CCNA2 | |
| SCHEMBL12824674 | 0.70 | CCNK (0.47) | HRH4IKBKBKAT2BCDK1CCNA2 | |
| SCHEMBL22895374 | 0.70 | MAPK1 (0.53) | IKBKBKAT2B | |
| SCHEMBL359361 | 0.70 | — | — | |
| SCHEMBL81623 | 0.70 | — | — | |
| SCHEMBL172577 | 0.70 | — | — | |
| Hydrochloric Acid SCHEMBL4335250 | 0.68 | KAT2B (0.36) | HRH4KAT2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8188100-B2 | Adenosine derivatives as A2A receptor agonists | NOVARTIS AG (CH) | 2012-05-29 | — | — | US | disclosed |
| US-8188100-B2 | Adenosine derivatives as A2A receptor agonists | NOVARTIS AG (CH) | 2012-05-29 | — | — | US | disclosed |
| US-20090325967-A1 | ADENOSINE DERIVATIVES AS A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2009-12-31 | — | — | US | disclosed |
| US-20090325967-A1 | ADENOSINE DERIVATIVES AS A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2009-12-31 | — | — | US | disclosed |
| EP-1903044-A1 | Adenosine Derivatives as A2A Receptor Agonists | Novartis AG (CH) | 2008-03-26 | — | — | EP | disclosed |
| WO-2008031875-A1 | ADENOSINE DERIVATIVES AS A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325967-A1 | ADENOSINE DERIVATIVES AS A2A RECEPTOR AGONISTS | ADORA2A, ADORA2B, ADORA1 | HRH4 248/4885IKBKB 1384/4885KAT2B 3824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.